Literature DB >> 34354853

A review of gliomas-related proteins. Characteristics of potential biomarkers.

Tomasz Pienkowski1, Tomasz Kowalczyk1, Adam Kretowski1, Michal Ciborowski1.   

Abstract

Brain tumors are one of the most commonly diagnosed cancers of the central nervous system. Of all diagnosed malignant tumors, 80% are gliomas. An unequivocal diagnosis of gliomas is not always simple, and there is a great need for research to find new treatment options and diagnostic approaches. This paper is focused on the glioma-related protein profiles as compared to healthy brain tissue, which is reflected in multiple correlations between biological aspects that influence proliferation, apoptosis evasion and the invasiveness of neoplastic cells. The work presents the possibilities of facilitating clinical practice with proteomic biomarkers, which offer a wider diagnostic spectrum and reduce the margin of mistake in histopathological or imaging diagnostic methods. In fact, many changes in the body's homeostasis can be overlooked due to the lack of symptoms or their non-specificity. Nevertheless, a single marker has limited reliability in distinguishing a particular tumor subtype, since the increased or decreased level of the protein of interest may differ between the stages or locations of the tumor. Moreover, the correlations between proposed proteins - presented in this paper - may help clinicians to choose the most optimal therapy, and estimate its effectiveness, or indicate new therapeutic targets affecting disrupted biochemical pathways. AJCR
Copyright © 2021.

Entities:  

Keywords:  GBM; biochemistry; biomarkers; glioma; proteomics

Year:  2021        PMID: 34354853      PMCID: PMC8332856     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  1 in total

1.  Clinical and Prognostic Implications of 1p/19q, IDH, BRAF, MGMT Promoter, and TERT Promoter Alterations, and Expression of Ki-67 and p53 in Human Gliomas.

Authors:  Zixi Yang; Feng Ling; Sibei Ruan; Jiajia Hu; Mingxi Tang; Xingwang Sun; Wenbo Long
Journal:  Cancer Manag Res       Date:  2021-11-23       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.